全文获取类型
收费全文 | 143088篇 |
免费 | 11246篇 |
国内免费 | 486篇 |
专业分类
耳鼻咽喉 | 1730篇 |
儿科学 | 3733篇 |
妇产科学 | 3025篇 |
基础医学 | 19199篇 |
口腔科学 | 2787篇 |
临床医学 | 16420篇 |
内科学 | 28008篇 |
皮肤病学 | 1921篇 |
神经病学 | 13545篇 |
特种医学 | 5302篇 |
外国民族医学 | 4篇 |
外科学 | 22116篇 |
综合类 | 1970篇 |
一般理论 | 160篇 |
预防医学 | 12671篇 |
眼科学 | 2725篇 |
药学 | 9978篇 |
中国医学 | 165篇 |
肿瘤学 | 9361篇 |
出版年
2023年 | 651篇 |
2022年 | 562篇 |
2021年 | 2660篇 |
2020年 | 1711篇 |
2019年 | 2749篇 |
2018年 | 3306篇 |
2017年 | 2372篇 |
2016年 | 2670篇 |
2015年 | 2993篇 |
2014年 | 4427篇 |
2013年 | 6238篇 |
2012年 | 9554篇 |
2011年 | 10015篇 |
2010年 | 5742篇 |
2009年 | 5158篇 |
2008年 | 8930篇 |
2007年 | 9313篇 |
2006年 | 8998篇 |
2005年 | 8680篇 |
2004年 | 8416篇 |
2003年 | 7694篇 |
2002年 | 7395篇 |
2001年 | 2382篇 |
2000年 | 2143篇 |
1999年 | 2251篇 |
1998年 | 1810篇 |
1997年 | 1416篇 |
1996年 | 1169篇 |
1995年 | 1145篇 |
1994年 | 1023篇 |
1993年 | 979篇 |
1992年 | 1551篇 |
1991年 | 1443篇 |
1990年 | 1346篇 |
1989年 | 1229篇 |
1988年 | 1132篇 |
1987年 | 1167篇 |
1986年 | 1095篇 |
1985年 | 1157篇 |
1984年 | 1000篇 |
1983年 | 840篇 |
1982年 | 744篇 |
1981年 | 614篇 |
1980年 | 570篇 |
1979年 | 665篇 |
1978年 | 560篇 |
1977年 | 462篇 |
1976年 | 442篇 |
1974年 | 436篇 |
1973年 | 401篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
3.
4.
5.
6.
7.
Timothy J. Cordingley Mark A.G. Wilson Kathryn M. Weston 《Health & social care in the community》2022,30(1):353-359
Vaccination is a vital health care initiative to prevent individual and population infection. To increase vaccination rates the federal government implemented the ‘No Jab, No Pay’ policy, where eligibility for several government benefits required children to be fully vaccinated by removing ‘conscientious objections’ and expanding the age range of children whose families receive benefits. This study assesses the impact of this policy at a local area within a single medical practice community in NSW, Australia. A retrospective clinical audit was performed between 2012 and 2017 on a single general practice's vaccination records for children ≤19 years. Catch-up vaccinations were assessed based on age at vaccination. Incidence of catch-up vaccinations was assessed for each of four years before and two years after the implementation of the ‘No Jab, No Pay’ policy in January 2016, along with the age of children and vaccination(s) given. Catch-up vaccinations were assessed temporally either side of implementation of ‘No Jab, No Pay’. Comparing the average annual vaccination catch-up incidence rate of 6.2% pre-implementation (2012–2015), there was an increase to 9.2% in 2016 (p < .001) and 7.8% in 2017 (p = .027). Secondary outcome measurement of catch-up vaccination incidence rates before (2012–2015) and after (2016–2017) ‘No Jab, No Pay’ implementation showed statistically significant increases for children aged 8–11 years (3.2%–5.6%, p = .038), 12–15 years (7.5%–14.7%, p < .001) and 16–19 years (3.3%–10.2%, p < .001) along with a statistically significant reduction in children aged 1–3 years (11.4%–6.2%, p = .015). Also, catch-up rates for DTPa significantly increased after program implementation. This study demonstrates that the Australian federal government vaccination policy ‘No Jab, No Pay’ was coincident with an increase in catch-up vaccinations within a rural NSW community served by one medical practice, especially for older children. 相似文献
8.
9.
10.
Liam Masterson James Howard Jazmina Gonzalez-Cruz Christopher Jackson Catherine Barnett Lewis Overton Howard Liu Rahul Ladwa Fiona Simpson Margie McGrath Ben Wallwork Terry Jones Christian Ottensmeier Melvin L.K. Chua Chris Perry Rajiv Khanna Benedict Panizza Sandro Porceddu Matt Lechner 《International journal of cancer. Journal international du cancer》2020,146(8):2305-2314
Now is an exciting era of development in immunotherapy checkpoint inhibitors and their effect on the treatment of NPC. While the general prognosis of R/M disease is poor, immunotherapy offers some promise in a malignancy associated with EBV and characterized by a peritumoural immune infiltrate. Our study aims to review past and on-going clinical trials of monoclonal antibody therapies against the checkpoint inhibitors (e.g. PD1 and CTLA-4), in R/M NPC. All randomized and nonrandomized controlled trials involving immune checkpoint inhibitor interventions for treatment of NPC were included in the study. We utilized a validated “risk of bias” tool to assess study quality. Four separate Phase I–II trials report the potential of PD1 inhibitor treatment for patients with NPC. Within the observed groups, camrelizumab combined with chemotherapy achieved an objective response in 91% of patients as first-line treatment for metastatic NPC (PFS 68% at 1-year) but this was associated with a high rate of grade >3 adverse events (87%; CTCAE version 4.03). The remaining three studies focused on recurrent NPC disease in patients who had received at least one line of prior chemotherapy. Within this group, camrelizumab monotherapy achieved an objective response in 34% of patients (PFS 27% at 1-year; range across all three studies 20.5–34%). No NPC trial has yet reported on specific outcomes for non-PD1 checkpoint inhibitors but 11 on-going studies include alternative targets (e.g. PD-L1/CTLA-4) as combination or monotherapy treatments. In considering checkpoint immunotherapies for NPC, initial results show promise for anti-PD1 interventions. Further phase I–III trials are in progress to clarify clinical outcomes, fully determine safety profiles, and optimize drug combinations and administration schedules. 相似文献